ePrints

Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Lookup NU author(s): Professor Helen ReevesORCiD

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Publication metadata

Author(s): Cappuyns S, Piqué-Gili M, Esteban-Fabró R, Philips G, Balaseviciute U, Pinyol R, Gris-Oliver A, Vandecaveye V, Abril-Fornaguera J, Montironi C, Bassaganyas L, Peix J, Zeitlhoefler M, Mesropian A, Huguet-Pradell J, Haber PK, Figueiredo I, Ioannou G, Gonzalez-Kozlova E, D'Alessio A, Mohr R, Meyer T, Lachenmayer A, Marquardt JU, Reeves HL, Edeline J, Finkelmeier F, Trojan J, Galle PR, Foerster F, Mínguez B, Montal R, Gnjatic S, Pinato DJ, Heikenwalder M, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, Llovet JM

Publication type: Article

Publication status: Published

Journal: Journal of Hepatology

Year: 2025

Volume: 82

Issue: 6

Pages: 1036-1049

Print publication date: 01/06/2025

Online publication date: 19/12/2024

Acceptance date: 07/12/2024

Date deposited: 14/02/2025

ISSN (print): 0168-8278

ISSN (electronic): 1600-0641

Publisher: Elsevier BV

URL: https://doi.org/10.1016/j.jhep.2024.12.016

DOI: 10.1016/j.jhep.2024.12.016

Data Access Statement: RNA sequencing data of the Inhouse RNAseq Cohort, generated for the purpose of this study, will be deposited at the European Genome phenome Archive (EGA; https://ega-archive.org) upon publication.

PubMed id: 39709141

Altmetrics

Funding

Share